India Has Enough Drugs And Medicines To Deal With Any Contingency Arising Out Of Impact Of CoronaVirus

Image
Capital Market
Last Updated : Feb 18 2020 | 1:04 PM IST

Keeping in view India's over dependence on import of Active Pharmaceutical Ingredients (APIs), Government of India has constituted a Task Force on APIs under the chairmanship of Minister of State for Shipping (I/C) and Chemicals & Fertilizers Mansukh Mandaviya to formulate a road map for the enhanced production of APIs in the country. The 5th Meeting of the Task Force was held yesterday. Several important issues were discussed regarding policy relaxations to small, medium and large API units and also simplification of the process for environment clearance for production and availability of medicines.

Mansukh Mandaviya took stock of the situation of availability of drugs and medicines. The Industry Representatives has explained thoroughly to Mansukh Mandaviya that they have enough drugs and medicines to deal with any contingency arising out of impact of CoronaVirus. They ensured that there will be no shortage of any Drugs, APIs and Medicines in the coming days in India. During the meeting, the challenges faced by the Pharmaceutical Industry in obtaining Environment Clearance were also discussed. The representative of Ministry of Environment and Forest, Climate Change (MoEF&CC) has stated that steps are being taken to expedite Environment Clearances and also mentioned that recently MoEF&CC has modified the guidelines so that there is no need to obtain separate Environment Clearance, if the production of the Pharma unit is increased by 50%.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 18 2020 | 12:42 PM IST

Next Story